AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-30 (Cancelled)

31. (Previously presented) A method of treatment of the human or animal body, said method comprising administering an effective, non-toxic amount of a pharmaceutical composition comprising:

(a) an expression cassette operably linked to (i) a myosin light chain enhancer; (ii) a promoter selected from a myosin heavy chain promoter and a viral promoter; and (iii) a polynucleotide sequence encoding a polypeptide of therapeutic use, ~~or which is expressed to generate a therapeutic product which is an RNA~~;

(b) a vector comprising said expression cassette; or

(c) a viral strain comprising said expression cassette

combined with a pharmaceutically acceptable carrier or diluent.

32. (Previously presented) The method of claim 31, wherein said vector is a plasmid vector or a viral vector.

33. (Previously presented) The method of claim 31, wherein said expression cassette is administered as a naked nucleic acid construct.

34. (Previously presented) The method of claim 31, wherein said pharmaceutical composition is formulated for intramuscular administration.

35. (Previously presented) The method of claim 31, wherein said myosin light chain enhancer is a myosin light chain 1/3 enhancer.

36-39 (Cancelled)

40. (Previously presented) The method of claim 31, wherein said viral promoter is a cytomegalovirus promoter or a herpes simplex virus promoter.

41. (Previously presented) The method of claim 31, wherein said vector further comprises fish or mammalian genomic sequences flanking said expression cassette.

42. (Previously presented) The method of claim 31, wherein said vector further comprises viral genomic sequences flanking said expression cassette.

43-50 (Cancelled)

51. (Previously presented) The method of claim 31, wherein said polynucleotide comprises a heterologous gene.

52-57 (Cancelled)

58. (Previously presented) A method of treatment of the human or animal body, said method comprising administering an effective, non-toxic amount of a pharmaceutical composition comprising:

(a) an expression cassette operably linked to (i) a myosin light chain enhancer; (ii) a promoter selected from a myosin heavy chain promoter and a viral promoter; and (iii) a polynucleotide sequence encoding a polypeptide of therapeutic use which is not a blood coagulation factor, ~~or which is expressed to generate a therapeutic product which is an RNA;~~

(b) a vector comprising said expression cassette; or

(c) a viral strain comprising said expression cassette;

combined with a pharmaceutically acceptable carrier or diluent.

59. (Previously presented) The method of claim 58, wherein said vector is a plasmid vector or a viral vector.

60. (Previously presented) The method of claim 58, wherein said expression cassette is administered as a naked nucleic acid construct.

61. (Previously presented) The method of claim 58, wherein said pharmaceutical composition is formulated for intramuscular administration.

62. (Previously presented) The method of claim 58, wherein said myosin light chain enhancer is a myosin light chain 1/3 enhancer.

63-66 (Cancelled)

67. (Previously presented) The method of claim 58, wherein said viral promoter is a cytomegalovirus promoter or a herpes simplex virus promoter.

68. (Previously presented) The method of claim 58, wherein said vector further comprises fish or mammalian genomic sequences flanking said expression cassette.

69. (Previously presented) The method of claim 58, wherein said vector further comprises viral genomic sequences flanking said expression cassette.

70-77 (Cancelled)

78. (Previously presented) The method of claim 58, wherein said polynucleotide comprises a heterologous gene.

79-96 (Cancelled)